132 related articles for article (PubMed ID: 6440313)
1. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
[TBL] [Abstract][Full Text] [Related]
2. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
Minami N; Ikeda Y; Abe M
Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
5. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
Jennings PE; Belch JJ
Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
[TBL] [Abstract][Full Text] [Related]
6. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
Chan TK; Chan V; Teng CS; Yeung RT
Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
[TBL] [Abstract][Full Text] [Related]
7. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
8. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
Diabetes Res Clin Pract; 1988 Jul; 5(2):81-90. PubMed ID: 3416710
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
Rupprecht E; König E; Limmer J
Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
[No Abstract] [Full Text] [Related]
10. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
Harrower AD
Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
[TBL] [Abstract][Full Text] [Related]
11. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
[TBL] [Abstract][Full Text] [Related]
12. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
[TBL] [Abstract][Full Text] [Related]
13. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Saberi M; Ramazani Z; Rashidi H; Saberi A
Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.
Jerums G; Murray RM; Seeman E; Cooper ME; Edgley S; Marwick K; Larkins RG; Martin TJ
Diabetes Res Clin Pract; 1987; 3(2):71-80. PubMed ID: 3552537
[TBL] [Abstract][Full Text] [Related]
15. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
[TBL] [Abstract][Full Text] [Related]
16. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
17. Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
Tessier D; Dawson K; Tétrault JP; Bravo G; Meneilly GS
Diabet Med; 1994 Dec; 11(10):974-80. PubMed ID: 7895463
[TBL] [Abstract][Full Text] [Related]
18. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
Collier A; Watson HH; Patrick AW; Ludlam CA; Clarke BF
Diabete Metab; 1989; 15(6):420-5. PubMed ID: 2534084
[TBL] [Abstract][Full Text] [Related]
19. Sulfonylureas and platelet function.
Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
[TBL] [Abstract][Full Text] [Related]
20. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
